These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22607900)

  • 1. Considerations for controlling invasive meningococcal disease in high income countries.
    Holst J; Nøkleby H; Bettinger JA
    Vaccine; 2012 May; 30 Suppl 2():B57-62. PubMed ID: 22607900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing and dynamic epidemiology of meningococcal disease.
    Halperin SA; Bettinger JA; Greenwood B; Harrison LH; Jelfs J; Ladhani SN; McIntyre P; Ramsay ME; Sáfadi MA
    Vaccine; 2012 May; 30 Suppl 2():B26-36. PubMed ID: 22178525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
    Pace D
    Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.
    Sáfadi MA; McIntosh ED
    Expert Rev Vaccines; 2011 Dec; 10(12):1717-30. PubMed ID: 22085175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
    Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
    J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations.
    Baker CJ
    J Adolesc Health; 2016 Aug; 59(2 Suppl):S29-37. PubMed ID: 27449147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serogroup B meningococcal vaccines.
    Zimmer SM; Stephens DS
    Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.